A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers

This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.

Inclusion Criteria:

• Patient participated in one of the five vorinostat base protocols, has not shown tumor progression on that study, and has tolerated the study drug
• Patient did not withdraw from the base protocol
• Patient agrees to practice effective birth control during the study

Exclusion Criteria:

• Patient is receiving other standard and/or investigational anticancer therapy
• Patient has any condition or disease that would interfere with compliance or pose addition risk in administering the study drug